Malignant Central Nervous System Neoplasm

Malignant Central Nervous System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 822
Recruiting: 449
Ph III recruiting: 27
Growth YoY: +18.1%
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.9%
Trials / 1,000 deaths: 45.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (418)

clinicaltrialsPublishedShowing 151–200 of 2,864 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05303519	SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)(SIGMA)	recruiting	Phase 3	365	Nuvation Bio Inc.INDUSTRY	3	Aug 28, 2026	clinicaltrials
NCT07420543	Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach(FLUO-LB)	active not recruiting	—	30	Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER	1	Aug 28, 2026